By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Bristol-Myers Squibb Pharmaceutical Research Institute 

Route 206, Provinceline Road
P.O. Box 4000
Princeton  New Jersey  08543  U.S.A.
Phone: 609-252-4000 Fax: n/a

The Bristol-Myers Squibb Pharmaceutical Research Institute (PRI) is one of the world's most productive, respected, and innovative research organizations. The PRI is dedicated to discovering and developing innovative, cost-effective medicines that address significant unmet medical needs and enhance and extend human life.


  • Established in 1938
  • 1999 research and development budget nearly $2 billion
  • Over 4,500 scientific and administrative personnel worldwide, and growing
  • More than 50 compounds in active development

    The BMS Pharmaceutical Research Institute has four major sites in the United States, linked to a network of smaller centers worldwide:

    Princeton, New Jersey:
    PRI headquarters, oncology drug discovery, immunology, inflammation, and pulmonary drug discovery, discovery chemistry, clinical research and development, worldwide regulatory affairs
    New Brunswick, New Jersey:
    Pharmaceutical development, worldwide regulatory affairs
    Hopewell, New Jersey:
    Cardiovascular drug discovery, metabolic diseases drug discovery, applied genomics, bioprocess sciences, discovery chemistry, worldwide regulatory affairs
    Wallingford, Connecticut:
    Infectious disease drug discovery, neuroscience drug discovery, genitourinary drug discovery, clinical research and development, lead discovery, high throughput screening, natural product screening, worldwide regulatory affairs


    Peter Ringrose, PhD, president of the Pharmaceutical Research Institute and chief scientific officer of Bristol-Myers Squibb Company, has focused on creating the most productive, respected and innovative drug discovery organization in the world. The PRI growth strategy centered on the discovery, development, and approval of novel medicines that address significant unmet medical needs will fundamentally drive the company's future goals and vision. The PRI is a horizontal process-based organization that emphasizes innovation, flexibility, speed, and efficiency. The organization focuses on the four key processes that are critical to successful pharmaceutical research and development, exemplified by the PRI's four principle governing committees: the Lead Development Operating Committee (target and lead identification), the Exploratory Development Operating Committee (lead optimization and proof of principle), the Full Development Operating Committee (full development and life cycle management), and the Licensing Management Committee (licensing and external development).


    BMS is a world leader in providing life-saving and life-extending oncology therapies for patients with cancer, and offers 19 anticancer and supportive care products in the United States. Among the company's products are TAXOL® (paclitaxel), for the treatment of patients with breast, lung, and ovarian cancers, and AIDS-related Kaposi's sarcoma. All of the company's resources and expertise in oncology research and development are marshaled toward the single goal of providing safer and more effective cancer medicines. Among the areas of research in which BMS has promising drug candidates are epothilones, taxanes, tumor vascular targeting, matrix metalloproteinase inhibitors, hormonal mechanisms, ras pathway, and chemoprevention.

    Cardiovascular and Metabolic Disease
    In the United States, cardiovascular disease is our number one killer and is responsible for nearly one million deaths annually. The direct cost of cardiovascular disease is estimated at over $150 billion; the cost in human suffering is immeasurable. PRAVACHOL® (pravastatin), a cholesterol-lowering drug, is the company's leading metabolic product. Principal research targets in these therapeutic areas include hypertension, arrhythmia, ischemia, atherosclerosis, thrombosis, heart failure, diabetes, obesity, and lipid disorders.

    Infectious Disease
    Bristol-Myers Squibb has been at the forefront of infectious diseases research for a half century. The company currently markets the broad-spectrum antibiotic TEQUIN® (gatifloxacin), and VIDEX® (didanosine) and ZERIT® (stavudine) for the treatment of patients with HIV/AIDS. Despite the great advances made against infectious diseases, such crises as the emergence of the AIDS/HIV epidemic and increasing bacterial drug resistance present serious threats to worldwide health. Bristol-Myers Squibb continues its lead in the area of infectious diseases drug discovery and development in many research areas, including AIDS/HIV, hepatitis, drug resistant bacteria, and broad-spectrum antifungals.

    Neuro-psychiatric diseases such as dementia and schizophrenia are associated with enormous individual and societal cost. Unfortunately, there are no effective disease-modifying treatments for many of these diseases. Among the Bristol-Myers Squibb marketed products for central nervous system disorders include SERZONE® (nefazadone) for depression and BUSPAR® (buspirone) for anxiety. Key areas of research include schizophrenia, stroke, Alzheimer's disease, obesity, male erectile dysfunction, and pain.

    Other Therapeutic Areas
    Bristol-Myers Squibb is concentrating on a number of other therapeutic areas, including immunology and inflammation (autoimmune/inflammatory disorders, rheumatoid arthritis, organ transplantation); pulmonary disease (asthma, chronic obstructive pulmonary disease, allergic rhinitis); and dermatology (inflammatory diseases, excessive hair growth, pigmentation, psoriasis, wound healing). In July, 2000, the FDA approved VANIQATM (eflornithine hydrochloride) as the first topical prescription treatment for women with unwanted facial hair.


    Bristol-Myers Squibb's drug discovery program includes many biotechnology alliances and collaborative agreements. These agreements bring new products into the pipeline or help the company remain on the cutting edge of technology in the search for novel medicines. Areas of great promise include applied genomics and pharmacogenomics, where internal company efforts together with key alliances and collaborative arrangements help expand the company's understanding of the role of genes in disease, but will ultimately help deliver the most effective therapies to individual patients. The company currently has about 50 major alliances with biotech companies and academic centers. Among them are:

  • Millennium Predictive Medicines: cancer pharmacogenomics
  • Karolinska Institute: clinical cancer pharmacogenomics
  • Xenova Group plc: Screening collaboration
  • Incyte Pharmaceuticals: DNA sequence/gene expression database
  • Whitehead Institute/MIT, Millennium, Affymetrix: Research program in functional genomics
  • Ligand Pharmaceuticals: Mineralocorticoid receptor modulators for cardiovascular diseases
  • Exelixis: Model systems and drug target validation strategies
  • Research Triangle Institute: Camptothecin analogs
  • SIBIA: Development of novel treatments for Alzheimer's disease
  • GBF: Collaboration to develop anticancer epothilones
  • Genome Therapeutics: Microbial genome research
  • KaroBio: Collaboration in metabolic disorders
  • Pharmacopeia: Collaboration regarding chemokine receptors
  • University Louis Pasteur, Strasbourg, France: genetics, molecular and cellular biology
  • Oxford University, England: neurosciences, Alzheimer's disease
  • Samuel Lunenfeld Research Institute/Mt. Sinai Hospital, Toronto: molecular biology
  • Massachusetts General Hospital: melatonin and sleep disorders
  • Massachusetts General Hospital: neurogenetics


    On April 27, 1999, President Clinton presented the National Medal of Technology, the nation's highest recognition for technological innovation, to Charles A. Heimbold, Jr., chairman and CEO of Bristol-Myers Squibb. The Medal was awarded to Bristol-Myers Squibb "for extending and enhancing human life through innovative pharmaceutical research and development, and for redefining the science of clinical study through groundbreaking and hugely complex clinical trials that are recognized models in the industry."

    Through the PRI's initiatives in genomics, high throughput screening, computer assisted drug design, pharmaceutical research in space, and other advanced technologies, Bristol-Myers Squibb enters the new millennium as an innovative leader in the quest for the medicines of the future. Indeed, Bristol-Myers Squibb's pipeline is arguably the best in the industry.

    For additional information on Bristol-Myers Squibb research initiatives, or to obtain information concerning Bristol-Myers Squibb products, call 609-252-3208 or visit us at

    Last Updated: 01-20-05

    Key Statistics

    Ownership: Public

    Web Site: Bristol-Myers Squibb Pharmaceutical Research Institute
    Employees: 44,000
    Symbol: BMY

  • Collaborations

    Cadus Corporation  Focus on the development of drug discovery assays

    Cephalon  Stadol NS® for pain management and Serzone® (nefazodone hydrochloride) for depression

    Exelixis  Mechanism of Action, Agreement signed September 1999, expanded June 2000

    Oxford Instruments 

    Applied Molecular Evolution/Eli Lilly 

    Company News
    Bristol-Myers Squibb Company (BMY) Prices Tender Offer10/19/2005 5:13:10 PM
    Bristol-Myers Squibb Company (BMY) Invites Yahoo!'s Global Audience To Shine A Light On HIV/AIDS Epidemic On World AIDS Day10/19/2005 5:12:20 PM
    Bristol-Myers Squibb Company (BMY) To Host Research And Development Overview With Financial Analysts On November 17, 2004 10/19/2005 5:12:11 PM
    Medarex Partners Up Again10/19/2005 5:12:07 PM
    Medarex, Inc. (MEDX) To Host Conference Call Today To Discuss Bristol-Myers Squibb Company (BMY) Development And Commercialization Collaboration For MDX-01010/19/2005 5:12:06 PM
    Bristol-Myers Squibb Foundation And China Foundation For Hepatitis Prevention And Control Collaborate To Fight One Of China's Most Pressing Health Problems10/19/2005 5:12:02 PM
    Bristol-Myers Squibb Company (BMY) Use Of Investigational Agent Entecavir Demonstrated Statistically Significant Improvement In Liver Histology And Viral Suppression Compared To Lamivudine In Chronically Infected Hepatitis B E-Antigen (HBeAg) Positive Patients10/19/2005 5:12:00 PM
    Bristol-Myers Squibb Company (BMY) Appoints Dr. Elliott Sigal Chief Scientific Officer And President Of The Pharmaceutical Research Institute 10/19/2005 5:12:00 PM
    Elliott Sigal Named Acting President Of Bristol-Myers Squibb Pharmaceutical Research Institute10/19/2005 5:11:54 PM
    Bristol-Myers Squibb Company (BMY) Release: Pioneering Researchers Receive Distinguished Achievement Awards In Biomedicine10/19/2005 5:11:50 PM